Table 6.

Subgroup analysis of DAO.

Subgroup by		Studies	Participants	SMD (95% CI)	I2	P	P for heterogeneity
Country	Austria	3	117	-0.12[-0.49, 0.24]	0%	0.52	0.52
	China	2	151	-0.65 [-2.26, 0.96]	95%	0.43	<0.00001
Age	<18	1	90	-1.47[-1.94, -1.00]	NA	<0.00001	NA
	≥18	4	178	-0.02 [-0.32, 0.28]	0%	0.89	0.54
Design	Placebo	3	150	0.04 [-0.28, 0.36]	0%	0.80	0.53
	Conventional treatment	2	118	-0.95 [-2.04, 0.15]	84%	0.09	0.01
Duration of treatment	< 2 weeks	2	151	-0.65 [-2.26, 0.96]	95%	0.43	<0.00001
	≥2 weeks	3	117	-0.12 [-0.49, 0.24]	0%	0.52	0.52